Market Cap 122.41B
Revenue (ttm) 47.92B
Net Income (ttm) 6.02B
EPS (ttm) N/A
PE Ratio 11.78
Forward PE 11.21
Profit Margin 12.55%
Debt to Equity Ratio 0.27
Volume 1,984,187
Avg Vol 3,030,242
Day's Range N/A - N/A
Shares Out 2.46B
Stochastic %K 51%
Beta 0.44
Analysts Strong Sell
Price Target $60.87

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 33 1 53 77 40 00
Address:
46, avenue de la Grande Armée, Paris, France
tsk93
tsk93 Dec. 4 at 4:49 PM
0 · Reply
BioRich
BioRich Dec. 4 at 4:21 PM
$XBI $ALT ***I CAN NOT EMPHASIZE THIS ENOUGH*** Following review of publicly available information, it appears that $ALT has now acknowledged that they: DID NOT PHYSICALLY DOSE AT LEAST ONE SUBJECT WITH WHAT THEY SAID THEY DID; THEY DOSED THEM WITH SOMETHING ELSE. This was discovered AFTER $ALT publicly published (and filed with the SEC) their (now questionable) dosing confirmation. From a process control, accountability and traceability standpoint, this is a significant concern IMHO. Short of it - $ALT is changing their tune on what PHYSICALLY happened. Before arguing, let that sink it. Data discussion is one thing. Changing what PHYSICALLY happened in the trial is another stratosphere of concern. (My observation from reviewing publicly available information. Further discussion/explanation available upon request). Cheers! $VKTX $MDGL $SNY
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 4:09 AM
Enter: $SNY Calls Strike Price: $50 Expiry Date: JAN 16 2026 Buy in Price: $1.61 - $1.85 Sell Price: $2.79 Profit : +73% (Turn every $1 into $1.73) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
wallstreet1929
wallstreet1929 Dec. 4 at 2:13 AM
$GANX looking ahead a tad... GANX # 2 development is for Gaucher disease - both this and PD are fundamentally two sides of the same coin: GCase deficiency. CEO has carved out a path for Phase 2 on PD via the ATM, but the readouts on Gcase activity could attract $SNY and $SAN, major players in lysosomal storage disorder and develop another track as P2 PD develops...
1 · Reply
ImNotLion
ImNotLion Dec. 3 at 5:48 PM
$ALT Time for the $SNY Durso to come out of the acquisition closet....
0 · Reply
ImNotLion
ImNotLion Dec. 3 at 3:35 PM
$ALT Durso was planted by $SNY to ride shotgun over their future 5 Billion dollar acquisition! Unpack the catalysts! 1 share for 1 share.
0 · Reply
ImNotLion
ImNotLion Dec. 3 at 3:23 PM
$ALT $SNY + Durso = Boom!! Very
0 · Reply
Power2k
Power2k Dec. 3 at 1:36 PM
$ALT why I think Pemvi is superior to FGF21s and THRb agonists? The latter don’t offer weight-loss benefits at all, plus they still pose significant side-effects, and if you would try to pair FGF21s or THRb agonists with GLP-1s or Amylin in some sort of combo approach, the tolerability issues will be enormous. On top of MASH resolution, Pemvi offers weight-loss effects with best lean muscle-retaining benefit which is second-to-none. It’s like having one drug working as a combo by itself, largely reducing side effects commonly seen in traditional combo therapies. Pemvi also beats Survodutide (another GLP-1/GCGR class of drug), as Pemvi shows much better tolerability and much earlier onset of MASH resolving effects. Pemvi is BIC, period. $SNY $AZN
0 · Reply
ImNotLion
ImNotLion Dec. 3 at 1:48 AM
$ALT $SNY Let me elaborate: 1. 1 share for 1 share exchange 2. 5 Billion outlay. 3. SNY has been buying up millions cheap via darkpool and open market. Enough to pay for P3 after deal is done. 4. The mystery of why we have been range bound for so long solved. 5. The mystery of why Garg has been as exciting as a knitting class, solved. Let the games begin!!!
2 · Reply
ImNotLion
ImNotLion Dec. 3 at 1:16 AM
$ALT It seems quite probable that $SNY has been calling the shots since Durst came onboard. They wanted him on board have the insider info. Now we see his very substantial vested 4 year compenstion options and know of his 20 year relationship with them....Is tomorrow time to announce the LOI and get on with the catalysts? Very
2 · Reply
Latest News on SNY
Press Release: Sanofi completes acquisition of Vicebio

Dec 4, 2025, 5:00 AM EST - 12 hours ago

Press Release: Sanofi completes acquisition of Vicebio


Bristol Myers, Sanofi sued by Texas over Plavix

Nov 20, 2025, 4:06 PM EST - 14 days ago

Bristol Myers, Sanofi sued by Texas over Plavix

BMY


Sanofi's type 1 diabetes drug recommended for EU approval

Nov 14, 2025, 8:21 AM EST - 20 days ago

Sanofi's type 1 diabetes drug recommended for EU approval


Sanofi: Is Dupixent Too Successful?

Oct 24, 2025, 2:32 PM EDT - 5 weeks ago

Sanofi: Is Dupixent Too Successful?


Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal

Oct 24, 2025, 1:37 PM EDT - 5 weeks ago

Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal


Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript

Oct 24, 2025, 1:37 PM EDT - 5 weeks ago

Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript

SAN


Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark

Oct 24, 2025, 10:47 AM EDT - 5 weeks ago

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark


Press release: Q3: continued sales and earnings progress

Oct 24, 2025, 1:30 AM EDT - 5 weeks ago

Press release: Q3: continued sales and earnings progress


ITM Appoints Annette Breunig as Chief People Officer

Oct 13, 2025, 5:00 AM EDT - 7 weeks ago

ITM Appoints Annette Breunig as Chief People Officer


Sanofi Expands Insulin Savings Program To Cover All US Patients

Sep 26, 2025, 1:40 PM EDT - 2 months ago

Sanofi Expands Insulin Savings Program To Cover All US Patients


Sanofi to offer all insulin products for $35 per month in US

Sep 26, 2025, 8:26 AM EDT - 2 months ago

Sanofi to offer all insulin products for $35 per month in US


Press release: Availability of the Q3 2025 Aide mémoire

Sep 24, 2025, 1:00 AM EDT - 2 months ago

Press release: Availability of the Q3 2025 Aide mémoire


tsk93
tsk93 Dec. 4 at 4:49 PM
0 · Reply
BioRich
BioRich Dec. 4 at 4:21 PM
$XBI $ALT ***I CAN NOT EMPHASIZE THIS ENOUGH*** Following review of publicly available information, it appears that $ALT has now acknowledged that they: DID NOT PHYSICALLY DOSE AT LEAST ONE SUBJECT WITH WHAT THEY SAID THEY DID; THEY DOSED THEM WITH SOMETHING ELSE. This was discovered AFTER $ALT publicly published (and filed with the SEC) their (now questionable) dosing confirmation. From a process control, accountability and traceability standpoint, this is a significant concern IMHO. Short of it - $ALT is changing their tune on what PHYSICALLY happened. Before arguing, let that sink it. Data discussion is one thing. Changing what PHYSICALLY happened in the trial is another stratosphere of concern. (My observation from reviewing publicly available information. Further discussion/explanation available upon request). Cheers! $VKTX $MDGL $SNY
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 4:09 AM
Enter: $SNY Calls Strike Price: $50 Expiry Date: JAN 16 2026 Buy in Price: $1.61 - $1.85 Sell Price: $2.79 Profit : +73% (Turn every $1 into $1.73) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
wallstreet1929
wallstreet1929 Dec. 4 at 2:13 AM
$GANX looking ahead a tad... GANX # 2 development is for Gaucher disease - both this and PD are fundamentally two sides of the same coin: GCase deficiency. CEO has carved out a path for Phase 2 on PD via the ATM, but the readouts on Gcase activity could attract $SNY and $SAN, major players in lysosomal storage disorder and develop another track as P2 PD develops...
1 · Reply
ImNotLion
ImNotLion Dec. 3 at 5:48 PM
$ALT Time for the $SNY Durso to come out of the acquisition closet....
0 · Reply
ImNotLion
ImNotLion Dec. 3 at 3:35 PM
$ALT Durso was planted by $SNY to ride shotgun over their future 5 Billion dollar acquisition! Unpack the catalysts! 1 share for 1 share.
0 · Reply
ImNotLion
ImNotLion Dec. 3 at 3:23 PM
$ALT $SNY + Durso = Boom!! Very
0 · Reply
Power2k
Power2k Dec. 3 at 1:36 PM
$ALT why I think Pemvi is superior to FGF21s and THRb agonists? The latter don’t offer weight-loss benefits at all, plus they still pose significant side-effects, and if you would try to pair FGF21s or THRb agonists with GLP-1s or Amylin in some sort of combo approach, the tolerability issues will be enormous. On top of MASH resolution, Pemvi offers weight-loss effects with best lean muscle-retaining benefit which is second-to-none. It’s like having one drug working as a combo by itself, largely reducing side effects commonly seen in traditional combo therapies. Pemvi also beats Survodutide (another GLP-1/GCGR class of drug), as Pemvi shows much better tolerability and much earlier onset of MASH resolving effects. Pemvi is BIC, period. $SNY $AZN
0 · Reply
ImNotLion
ImNotLion Dec. 3 at 1:48 AM
$ALT $SNY Let me elaborate: 1. 1 share for 1 share exchange 2. 5 Billion outlay. 3. SNY has been buying up millions cheap via darkpool and open market. Enough to pay for P3 after deal is done. 4. The mystery of why we have been range bound for so long solved. 5. The mystery of why Garg has been as exciting as a knitting class, solved. Let the games begin!!!
2 · Reply
ImNotLion
ImNotLion Dec. 3 at 1:16 AM
$ALT It seems quite probable that $SNY has been calling the shots since Durst came onboard. They wanted him on board have the insider info. Now we see his very substantial vested 4 year compenstion options and know of his 20 year relationship with them....Is tomorrow time to announce the LOI and get on with the catalysts? Very
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 2 at 9:26 PM
Enter: $SNY Calls Strike Price: $52 Expiry Date: JAN 16 2026 Buy in Price: $0.95 - $1.00 Sell Price: $1.41 Profit : +48% (Turn every $1 into $1.48) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
JoeTheMiner
JoeTheMiner Dec. 2 at 8:53 PM
$LLY $NVO $SNY $XBI Time for $GUTS to shine 👑⭐🌟✨⚡
0 · Reply
BioRich
BioRich Dec. 2 at 8:50 PM
$GUTS getting juicy! Very excited about 6-month data that firther derisks this "sector-creating" treatment. Weight loss retension is the Holy Grail if Weight Loss and $GUTS has the market cornered. Recent financial moves make the financially de-risked and ready for acquistion or partnership. $LLY $NVO $SNY possible suitors? Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI
0 · Reply
Power2k
Power2k Dec. 2 at 4:25 PM
$ALT Why I think Pemvidutide totally beats Zealand/BI's Survodutide? #1 Pemvi’s 24-week topline MASH resolution rate (≈52–59%) is similar to Survodutide’s highest reported dose (62% at 4.8 mg) — but Survo’s results are at 48 weeks while Pemvi’s topline biopsy readout is at 24 weeks, which demonstrates an much earlier onset of efficacy of Pemvi as compared to Survo. #2 Survodutide (48 weeks): ≥1-stage fibrosis improvement occurred in 34% (2.4 mg), 36% (4.8 mg), 34% (6.0 mg) vs 22% with placebo which is stat significant. Pemvi (IMPACT 24-wk topline): Fibrosis improvement without worsening of MASH reported in 31.8% (1.2 mg) and 34.5% (1.8 mg) vs 25.9% for placebo which is not stat sig, however, this is a 24-week readout, and (imo) will achieve stat sig in the upcoming 48-wk readout. #3 Pemvi's safety profiles beat Survodutide's by a lot: Survo has a way higher rate of discontinuation due to AE (around 16-25%) while Pemvi shows only 0 to 1.2% of AE-related discontinuation. $SNY $AZN
4 · Reply
BioRich
BioRich Dec. 2 at 3:55 AM
$ALT This $ALT board is by far the worst on Stocktwits. $ALT could PR that they are discontinuing ALL trials, are filing for bankcrupt protection, dismissing ALL employees, and this board will spend the evening trying to convince each other that it just means there's a BO for $7B and that there will probably be a PR in the morning. I really don't think the PermaBulls understand how desperate and pitiful you look. Hell, with PermaBull logic/way of thinking, this move could mean that $IVA already has a deal done with $SNY. Truly pitiful. #27Dresses #CINO #WrongJab #PatientSafety #LossOfTrialControl #CEOousted
1 · Reply
Power2k
Power2k Dec. 2 at 1:54 AM
$ALT FGF21s and THRb drugs don’t offer weight-loss benefits at all, plus they still pose significant side-effects, and if you would try to pair them with GLP-1s or Amylin in some sort of combo approach, the tolerability issues will be enormous. On top of MASH resolution, Pemvi offers weight-loss effects with best lean muscle-retaining benefit which is second-to-none. It’s like having one drug working as a combo by itself, largely reducing side effects commonly seen in traditional combo therapies. $SNY $AZN
2 · Reply
BioRich
BioRich Dec. 1 at 4:26 PM
$ALT Friendly reminder is the sea of fruitless and desperate pumping on this board. @AryaRules This should help. As a side note, PermaBulls will tell you to look at Popular posts because hYpe and like each others' pumps and hate truth. They will also tell you to block me and Bears because they don't want you to see the reality on $ALT. To my credit, I called this move, the data delay, the data integrity concerns, the loss of trial control concerns, the massive dilutuon, the lawsuit status, the SEC concerns, the FDA concerns and so much more. $ALT PermaBulls will hYpe to cover their losses. I'll tell you how it is. They hate truth. Cheers! $XBI $SNY $VKTX $PFE
0 · Reply
JH2500
JH2500 Dec. 1 at 3:02 PM
$IMRX: IN more for $SNY, Sanofi BuyOut. News at any time...Goldman put $20 Target on $IMRX without the buyout two weeks ago.
0 · Reply
SuperPuncher
SuperPuncher Dec. 1 at 2:54 PM
$ALT $SNY LFG!! Well said diapers 🙏
0 · Reply
Diapers_Tequila
Diapers_Tequila Dec. 1 at 2:52 PM
$ALT Good luck to Dr. Garg in his retirement. Yes, I am extremely pleased with the news this morning and feel a massive amount of anxiety and weight off my shoulders. This is the most de-risking action in the history of Altimmune and gives the market the absolute green light that it is deal making time and the closers are now finally in the game and in control. The timing makes sense to me as well, we needed a new voice to champion the upcoming data catalysts and we couldn't risk the same playbook. Durso will bring the same energy and confidence that Linda has recently. It matters. Dr. Garg is a phenomenal science guy but the science is now done for Pemvi, the cake is baked. It is now deal making, relationship building, charismatic leader, and closer time. Massive kudos to Dr. Garg for having the awareness to understand his skill set is not what is needed right now. I can't wait to celebrate him and hope he makes an absolute killing on his 1.2 million shares. Rooting for people is way more fun and healthy than rooting against them. I would not be surprised to finally start seeing massive short covering, the main thesis has always ultimately been Dr. Garg, never Pemvi, that is now removed. It is also really hard to not make the very logical connection to $SNY with all of the appointments and now Durso becoming CEO and Chairman. Either way, Durso is a deal maker and it is go time.
7 · Reply
BioRich
BioRich Dec. 1 at 1:55 PM
$ALT Logic: 1) CEO knows 48W data + 2) CEO knows EoP2 meeting result + 3) CEO knows HUGE P3 for MASH agreed to + 4) Gets name off of massive Class Action lawsuit (for now) + 5) CEO Immediately leaves = Bullish. Can't make this stuff up folks. Facts trump.this stock. Sold all of my shares in anticpation of an entire closet of shoes dropping on this one. ***BUYER BEWARE*** $XBI $SNY $VKTX $PFE
1 · Reply
BioRich
BioRich Dec. 1 at 1:42 PM
$ALT ***BUYER BEWARE*** Durso's Potential Legal Trouble Ties: 1) Intercept Pharma under investigation 2) $SNY HQ just raided for Tax Fraud 3) $SNY Being sued by Texas AG for deceptive practices. 4) $ALT Still wrapped up in Class Action discussions for misleasing investors. The CA was recently voluntarily withdrawn with likely refiling as a Super-Case against $ALT. 5) $ALT subject to potential ongoing SEC investigation for misleading investors. 6) $ALT subject to potential ongoing FDA investigation for wrongfully performing invasive testing on subjects not requiring it. 7) $ALT subject to potential FDA investigation for losing control of their MASH P2b trial and dosing a subject with the Drug, rsrher than the Control (as they were assigned). I sold my shares and position Friday. Ive warned folks about what's happened with $ALT, what's happening with $ALT, and what their likely future is. $ALT delusionals want you to think this was a good thing. It's not. $XBI
2 · Reply